Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Acid Reducing Agents on Lumicitabine PK
NCT03468777Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lumicitabine in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Observed Plasma Concentration at 12 Hours Post dose, Observed Plasma Concentration at 24 Hours Post dose and 6 more. Started Mar 2018; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03468777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468777.